Below are summaries of recent ECOG-ACRIN-related analyses. Click on the shortened citation to access the publication.

Breast Cancer – For women with hormone receptor-positive (HR+) early breast cancer who are through menopause, 5-10 years of hormonal therapy with an aromatase inhibitor (AI) is standard following initial treatment. However, AIs carry high premature discontinuation rates due to the development of painful musculoskeletal symptoms, e.g., severe joint pain. E1Z11 is the first racially diverse study of MSS in this population. A Cohort Study to Evaluate Genetic Predictors for Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS): Results from ECOG-ACRIN E1Z11. Stearns V. Clin Cancer Res. April 2024

Leukemia – This laboratory study demonstrates a new framework for predicting effective combination therapies. It utilized biospecimen samples from patient cases in study E1910 and other sources. Single-cell systems pharmacology identifies development-driven drug response and combination therapy in B cell acute lymphoblastic leukemia. Huang X. Cancer Cell. April 2024

NCI-MATCH – A set of two companion manuscripts presents the findings from Arms K1 K2 of the trial, which evaluated the antitumor efficacy of the oral FGFR1-4 inhibitor erdafitinib.

• Phase II Study of Erdafitinib in Patients With Tumors With FGFR Amplifications: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1. Gong J. JCO Precis Oncol. April 2024
• Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2. Gong J. JCO Precis Oncol. April 2024